CSIMarket
 
Avadel Pharmaceuticals Plc  (NASDAQ: AVDL)
Other Ticker:  
 
 
Price: $8.2700 $0.36 4.551%
Day's High: $8.32 Week Perf: 15.99 %
Day's Low: $ 7.87 30 Day Perf: -4.17 %
Volume (M): 748 52 Wk High: $ 19.09
Volume (M$): $ 6,188 52 Wk Avg: $12.55
Open: $8.05 52 Wk Low: $6.38



 Market Capitalization (Millions $) 792
 Shares Outstanding (Millions) 96
 Employees 154
 Revenues (TTM) (Millions $) 169
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) 20
 Capital Exp. (TTM) (Millions $) 0

Avadel Pharmaceuticals Plc
Avadel Pharmaceuticals Plc is a pharmaceutical company that develops, manufactures, and commercializes various drugs primarily for sleep disorders and other central nervous system conditions. The company's products are designed to improve the quality and duration of sleep, providing patients with better sleep management options.

Avadel develops both branded and generic drugs and has a diverse product portfolio. Its flagship drug, FT218, is an extended-release formulation of sodium oxybate, which is used to treat narcolepsy. The company also offers other medications such as Bloxiverz, Vazculep, and Akovaz, which are used in anesthesia and related procedures.

In addition to its focus on sleep disorders, Avadel Pharmaceuticals is actively exploring potential opportunities within the pediatric market and other therapeutic areas. The company is committed to innovation and research, continuously working on developing new drugs and improving existing formulations to better serve patients' needs.

Avadel Pharmaceuticals operates globally and collaborates with partners and distributors to ensure the efficient production, marketing, and distribution of its drugs. The company is headquartered in Dublin, Ireland, and is publicly traded on the NASDAQ stock exchange under the ticker symbol AVDL.


   Company Address: 10 Earlsfort Terrace Dublin 2 0
   Company Phone Number: 901-5201   Stock Exchange / Ticker: NASDAQ AVDL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMRX     
BHC   -9.96%    
BMRN        0.99% 
JAZZ   -6.55%    
SRPT   -6.55%    
VRTX   -6.55%    
• View Complete Report
   



Management Changes

Avadel Pharmaceuticals Seeks Revival Amid Financial Struggles: New VP of Sales and Inducement Awards Signal Shift in Strategy

Published Mon, Feb 24 2025 1:01 PM UTC

Avadel Pharmaceuticals Seeks Revival Amid Financial Struggles: New VP of Sales and Inducement Awards Signal Shift in Strategy DUBLIN, Feb. 24, 2025 ? In a swift response to financial pressures, Avadel Pharmaceuticals plc (Nasdaq: AVDL) has announced the appointment of Kevin Springman as Vice President of Sales, aiming to revitalize its commercial strategy amidst a backdrop ...

Shares

Avadel Pharmaceuticals Bolsters Workforce with Inducement Awards Amid Share Price Challenges,

Published Mon, Jan 6 2025 9:05 PM UTC

Avadel Pharmaceuticals Announces Inducement Awards Amidst Ongoing DevelopmentsIn an effort to attract top-tier talent and drive continued growth, Avadel Pharmaceuticals plc (Nasdaq: AVDL) recently announced the approval of inducement awards aimed at new employees. The Dublin-based company, known for its focus on creating transformative medicines, has granted non-statutory op...

Clinical Study

Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ (sodium oxybate) Extended-Releas...

Published Wed, Sep 25 2024 12:01 PM UTC

An Examination of the Efficacy of LUMRYZ Extended-Release Oral Suspension in Ameliorating Symptoms of Narcolepsy: A PerspectiveEsteemed Scholars and Practitioners of the Pharmaceutical Arts,It is with great anticipation and intellectual fervor that we present to you the latest findings regarding the therapeutic efficacy of an advanced pharmaceutical agent, christened LUMRY...

Product Service News

One Dose Wonder Transforming Narcolepsy Treatment with Once-Nightly LUMRYZ,

Published Tue, Sep 3 2024 12:00 PM UTC

Rise and Shine: Impact of Once-Nightly LUMRYZ on Narcoleptic Patient Preference and Avadel Pharmaceuticals In the relentless pursuit of alleviating the burdens of narcolepsy, Avadel Pharmaceuticals has forged a significant path forward with its novel formulation, LUMRYZ. The recent publication of the RESTORE data brings forth compelling insights into the efficacy and patient...

Clinical Study

Efficacy of LUMRYZ in Weight Regulation Among Narcoleptic Subjects A Revolutionary Advancement in Therapeutics

Published Tue, Aug 20 2024 12:01 PM UTC

In the year of Our Lord, Two Thousand and Twenty-Four, as the march of medical science continues to unfold, it is with great fervour that we report developments in the field of pharmacotherapy for individuals afflicted with the malaise of narcolepsy. Avadel Pharmaceuticals plc, a biopharmaceutical entity dedicated to the art of medicine and the enhancement of human life, has...







Avadel Pharmaceuticals Plc's Segments

  Avadel Pharmaceuticals Plc Outlook

On January 8 2025 the Avadel Pharmaceuticals Plc provided following guidance

Avadel Pharmaceuticals Plc. has recently disclosed their financial projections, offering insights into their expected performance for the fourth quarter of 2024 and their strategic focus for 2025, particularly in relation to the launch of LUMRYZ.

The company anticipates generating around $50.0 million in net revenue from LUMRYZ sales for the final quarter of 2024. This estimate reflects a remarkable increase of over 150% compared to the $19.5 million reported for the same quarter in 2023. This significant growth indicates a robust market demand and effective commercialization strategies as Avadel pivots towards expanding the reach of LUMRYZ.

Furthermore, Avadel projects that by the close o...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com